Network Pharmacology and Molecular Docking Approaches of Astaxanthin (ATX) against Atherosclerosis

Pharmacognosy Research,2024,16,3,626-637.DOI:10.5530/pres.16.3.74Published:June 2024Type:Original ArticleAuthors:Anis Zuhaida Mamnun Barizi, Ain Nabila Syahira Shamsol Azman, Muhamad Fikri Shazlan Saad, Muhammad Nazrul Hakim Abdullah, Vuanghao Lim, and Yoke Keong Yong Author(s) affiliations:Anis Zuhaida Mamnun Barizi1, Ain Nabila Syahira Shamsol Azman1, Muhamad Fikri Shazlan Saad1, Muhammad Nazrul Hakim Abdullah2, Vuanghao Lim3, Yoke Keong Yong1,* 1Department of Human Anatomy, Faculty of Medicine and Health Sciences, University Putra Malaysia, Serdang, Selangor, MALAYSIA. 2Department of Biomedical Science, Faculty of Medicine and Health Sciences, University Putra Malaysia, Serdang, Selangor, MALAYSIA. 3Advanced Medical and Dental Institute, University Sains Malaysia, Bertam, Penang, MALAYSIA. Abstract:Background: Atherosclerosis is an inflammatory disease well known as the leading cause of Cardiovascular Diseases (CVDs). Astaxanthin (ATX) is a reddish pigment that belongs to the family of xanthophylls, which are oxygenated derivatives of carotenoids. Aim: In this study, we aimed to investigate the targets and mechanisms involved in treating atherosclerosis using network pharmacology and molecular approaches. Materials and Methods: The genes targeted by ATX were predicted using Swiss Target Prediction, BATMAN-TCM, and Super-Pred databases, while genes associated with atherosclerosis were retrieved from DigSee, GAD, GeneCards, and OMIM databases. The interactions between ATX and atherosclerosis genes were identified through protein–protein interaction analysis, Gene Ontology (GO) enrichment analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Results: The results revealed a total of 240 ATX-related genes and 4,977 atherosclerosis-related genes, with 172 overlapping genes identified. Six core genes were obtained: SRC, AKT1, MAPK3, HDAC1, PIK3R1, and RXRA. These results were further validated through the molecular docking approach, where all six core targets exhibit low binding energy, suggesting strong binding affinity, with PIK3R1 having the best binding affinity among them. Conclusion: Our study provides novel insights into the potential application of ATX in the management of atherosclerosis. Keywords:Astaxanthin, Atherosclerosis, Carotenoids, GO, KEGG, Network pharmacologyView:PharmacognRes-16-3-626.pdf (829.97 KB)